Anticonvulsant News and Research

RSS

$Researchers discover risk factors that contribute to fracture nonunion in adults$

Researchers discover risk factors that contribute to fracture nonunion in adults

Dr. Robert Zura, the Robert D'Ambrosia Professor and Head of Orthopaedic Surgery at LSU Health New Orleans School of Medicine, was part of a research team that identified risk factors which may help orthopaedic surgeons better predict a serious complication of bone fractures.

7 Sep 2016

FDA approves new ExAblate Neuro to treat patients with essential tremor

The U.S. Food and Drug Administration today approved the first focused ultrasound device to treat essential tremor in patients who have not responded to medication. ExAblate Neuro uses magnetic resonance (MR) images taken during the procedure to deliver focused ultrasound to destroy brain tissue in a tiny area thought to be responsible for causing tremors.

11 Jul 2016

Existing anti-inflammatory drugs may be effective in treating epilepsy

In epileptic patients, seizures lead to an increased level of inflammation-related proteins called chemokines in the brain, and systemic inflammation likely helps trigger and promote the recurrence of seizures, making inflammation a promising new target for anticonvulsant therapy.

6 Jul 2016

Epilepsy drug exposure does not increase newborn orofacial cleft risk

Pregnant women with epilepsy should not rule out continuing lamotrigine therapy due to concerns that exposure could increase the risk of orofacial clefts in their babies, say investigators.

7 Apr 2016

Anticonvulsant medication gabapentin effectively reduces common complication of PONV

The anticonvulsant medication gabapentin—already a useful part of strategies to control pain after surgery—also effectively reduces the common complication of postoperative nausea and vomiting (PONV), reports a study in Anesthesia & Analgesia.

23 Mar 2016

Study provides new insights into Retigabine drug

A study published ahead of print in the The Journal of General Physiology has revealed new insights into Retigabine, a known pharmacological treatment for epilepsy.

19 Feb 2016

UCI researchers uncover new underlying factor of seizures

University of California, Irvine researchers with the School of Medicine have identified the mechanism by which valproic acid controls epileptic seizures, and by doing so, also revealed an underlying factor of seizures.

15 Sep 2015

First drug produced by 3D printing is approved by FDA

Levetiracetam manufactured using three-dimensional (3D) printing has been approved by the US Food and Drug Administration (FDA) for the treatment of epilepsy.

5 Aug 2015

New epilepsy drug holds promise as Alzheimer's treatment

University of British Columbia researchers say a new epilepsy drug holds promise as a treatment for Alzheimer's disease.

7 May 2015

Electronic micropump combined with anticonvulsant drug may treat brain diseases

Many potentially efficient drugs have been created to treat neurological disorders, but they cannot be used in practice. Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain.

16 Apr 2015

UV researchers study neurobiological link between ASD and epilepsy

Researchers at the University of Veracruz (UV), in the west coast of Mexico, study the neurobiological link between the Autism Spectrum Disorder (ASD) and epilepsy, in order to understand the reason why the brain of an autistic child is 20-30 percent more susceptible to seizures that an infant without this condition.

6 Apr 2015

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI).

24 Mar 2015

Study: 31 states implement new policies for 'atypical' prescribing of antipsychotics to children

With a concern about inappropriate prescribing of antipsychotic medications to children, 31 states have implemented prior authorization policies for atypical antipsychotic prescribing, mostly within the past 5 years, and with most states applying their policies to children younger than 7 years of age, according to a study in the March 3 issue of JAMA.

4 Mar 2015

Retigabine drug shows promise in protecting the brain against effects of ischemic stroke

Retigabine, a drug approved to treat epilepsy, protected the brain against the effects of ischemic stroke in a study conducted at The University of Texas Health Science Center at San Antonio.

12 Feb 2015

Retigabine drug could reduce debilitating impact of strokes

New research suggests that an already-approved drug could dramatically reduce the debilitating impact of strokes, which affect nearly a million Americans every year.

5 Feb 2015

Anticonvulsant drug may help develop new class of antibiotics

McMaster scientists have found that an anticonvulsant drug may help in developing a new class of antibiotics.

23 Sep 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

A team of researchers from the National Institutes of Health, Emory University and Cedars-Sinai - specialists in identifying and treating very rare diseases - used three innovative tools to detect a previously unknown gene mutation, test potential therapies in the lab, and initiate personalized drug treatment for a boy with a lifelong history of uncontrollable seizures that caused significant impact on his cognitive and social development.

12 Mar 2014

Research findings have important implications for personalized treatment of alcohol abuse

Heavy drinking is common in the United States and takes a personal and societal toll, with an annual estimated cost of $223.5 billion due to losses in workplace productivity, health care and criminal justice expenses.

16 Feb 2014

Topiramate reduces drinking in patients committed to abstinence from alcohol

Heavy drinking alcohol consumption is common in the United States and takes a personal and societal toll, with an annual estimated cost of $223.5 billion due to losses in workplace productivity, and health care and criminal justice expenses.

14 Feb 2014